Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Journal of Public Health (Oxford, England)|April 4, 2019
The epidemiology and management of clusters of invasive meningococcal disease in England, 2010-15Maya Gobin, Gareth Hughes, Sarah Foulkes, et al.
Expert Opinion on Drug Safety|March 11, 2024
T-wave morphology abnormalities in the STREAM stage 1 trialGareth Hughes, William J Young, Henry Bern, et al.
PLOS Global Public Health|February 10, 2026
QT prolongation risk factors and a monitoring strategy in rifampicin-resistant tuberculosis: Findings from the STREAM Stage 2 trialGareth Hughes, Elena Frangou, Henry Bern, et al.
Zoonoses and Public Health|June 22, 2020
An outbreak of Shiga toxin-producing Escherichia coli O157:H7 linked to a mud-based obstacle course, England, August 2018Alexander Sharp, Elizabeth Smout, Lisa Byrne, et al.
Journal of Infection Prevention|October 10, 2017
A cross-sectional survey of the acceptability of data collection processes for validation of a European point prevalence survey of healthcare-associated infections and antimicrobial useLesley Price, Jacqui Reilly, Jon Godwin, et al.
Communications Biology|August 25, 2021
Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment responseTudor Petreus, Elaine Cadogan, Gareth Hughes, et al.
Open Research Europe|January 24, 2024
The ESCAPE Open-source Software and Service RepositoryThomas Vuillaume, Mohammad Al-Turany, Matthias Füßling, et al.
Pituitary|December 25, 2014
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trialJochen Schopohl, Feng Gu, Robert Rubens, et al.
BMJ Open|October 12, 2023
Evaluating the impact on health outcomes of an event that resulted in a delay in contact tracing of COVID-19 cases in England, September 2020: an observational studyLucy Findlater, Livia Pierotti, Charlie Turner, et al.
Endocrine-Related Cancer|July 19, 2012
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II studyLarry K Kvols, Kjell E Oberg, Thomas M O'Dorisio, et al.
Pageof 7